I am a Post-Doctoral Research Associate in the Williams-Gray/Barker lab at the John Van Geest Centre for Brain Repair. This work focusses on detecting and treating Parkinson’s Disease (PD) and the associated dementia (PDD) earlier across a few different studies. NET-PDD is an ongoing longitudinal study focussing on the progression of PD, the development of PDD, the PET imaging hallmarks via Tau ([18F]AV1451) as well as neuroinflammation via microglial activation ([11C]PK11195), the MRI-detected neuroanatomical signatures, the related blood/CSF cytokines, and the related bio-behavioural changes. AZA-PD is a clinical trial investigating the effects of the peripheral anti-inflammatory drug Azathioprine on PD progression, PET imaging via neuroinflammation via microglial activation ([11C]PK11195), s/f/dMRI hallmarks, blood/CSF cytokines, and behavioural measures of PD. This work is interested in peripheral and central nervous system inflammation being a principal driver of PD progression PDD, and the potential therapeutic targets for Parkinsonisms and dementia.
I am a Post-Doctoral Research Associate in the Williams-Gray/Barker lab at the John Van Geest Centre for Brain Repair. This work focusses on detecting and treating Parkinson’s Disease (PD) and the associated dementia (PDD) earlier across a few different studies. NET-PDD is an ongoing longitudinal study focussing on the progression of PD, the development of PDD, the PET imaging hallmarks via Tau ([18F]AV1451) as well as neuroinflammation via microglial activation ([11C]PK11195), the MRI-detected neuroanatomical signatures, the related blood/CSF cytokines, and the related bio-behavioural changes. AZA-PD is a clinical trial investigating the effects of the peripheral anti-inflammatory drug Azathioprine on PD progression, PET imaging via neuroinflammation via microglial activation ([11C]PK11195), s/f/dMRI hallmarks, blood/CSF cytokines, and behavioural measures of PD. This work is interested in peripheral and central nervous system inflammation being a principal driver of PD progression PDD, and the potential therapeutic targets for Parkinsonisms and dementia.